A
Allen John Lovey
Researcher at Hoffmann-La Roche
Publications - 44
Citations - 3003
Allen John Lovey is an academic researcher from Hoffmann-La Roche. The author has contributed to research in topics: Cancer & Cyclin-dependent kinase. The author has an hindex of 12, co-authored 44 publications receiving 2857 citations.
Papers
More filters
Journal ArticleDOI
9-cis retinoic acid stereoisomer binds and activates the nuclear receptor RXR alpha.
Arthur A. Levin,Laurie J. Sturzenbecker,Sonja Kazmer,Thomas Bosakowski,Christine Huselton,Gary Allenby,J Speck,C Kratzeisen,Michael Rosenberger,Allen John Lovey +9 more
TL;DR: The identification of a stereoisomer of retinoic acid, 9-cis retinol, which directly binds and activates RXRα, which suggests a new role for isomerization in the physiology of natural retinoids.
Journal ArticleDOI
Retinoic acid receptors and retinoid X receptors: interactions with endogenous retinoic acids
Gary Allenby,M T Bocquel,M Saunders,Sonja Kazmer,J Speck,Michael Rosenberger,Allen John Lovey,Philippe Kastner,Joseph F. Grippo,Pierre Chambon +9 more
TL;DR: 9-cis forms of endogenous retinoid can contribute to the pleiotropic effects of retinoids by interacting with both the RARs and RXRs.
Journal ArticleDOI
Discovery of RG7112: A Small-Molecule MDM2 Inhibitor in Clinical Development.
Binh Thanh Vu,Peter Michael Wovkulich,Giacomo Pizzolato,Allen John Lovey,Qingjie Ding,Nan Jiang,Jin-Jun Liu,Chunlin Zhao,Kelli Glenn,Yang Wen,Christian Tovar,Packman Kathryn E,Lyubomir T. Vassilev,Bradford Graves +13 more
TL;DR: RG7112 is the first clinical small-molecule MDM2 inhibitor designed to occupy the p53-binding pocket ofMDM2, which stabilizes p53 and activates the p 53 pathway, leading to cell cycle arrest, apoptosis, and inhibition or regression of human tumor xenografts.
Journal ArticleDOI
Activation of the p53 pathway by small-molecule-induced MDM2 and MDMX dimerization
Bradford Graves,Thelma Thompson,Mingxuan Xia,Cheryl Janson,Christine Lukacs,Dayanand Deo,Paola Di Lello,David C. Fry,Colin Garvie,Kuo-Sen Huang,Lin Gao,Christian Tovar,Allen John Lovey,Jutta Wanner,Lyubomir T. Vassilev +14 more
TL;DR: Dual MDM2/MDMX antagonists restored p53 apoptotic activity in the presence of high levels of MDMX and may offer a more effective therapeutic modality for MDMX-overexpressing cancers.
Journal ArticleDOI
Discovery of [4-Amino-2-(1-methanesulfonylpiperidin-4-ylamino)pyrimidin-5-yl](2,3-difluoro-6- methoxyphenyl)methanone (R547), a potent and selective cyclin-dependent kinase inhibitor with significant in vivo antitumor activity.
Xin-Jie Chu,Wanda DePinto,David Joseph Bartkovitz,Sung-Sau So,Binh Thanh Vu,Packman Kathryn E,Christine Lukacs,Qingjie Ding,Nan Jiang,Ka Wang,Petra Goelzer,Xuefeng Yin,Melissa Smith,Brian Higgins,Yingsi Chen,Qing Xiang,John Anthony Moliterni,Kaplan Gerald Lewis,Bradford Graves,Allen John Lovey,Nader Fotouhi +20 more
TL;DR: The 2,4-diamino-5-ketopyrimidines 6 reported here represent a novel class of potent and ATP-competitive inhibitors that selectively target the cyclin-dependent kinase family, and compound 39 demonstrates significant in vivo efficacy in the HCT116 human colorectal tumor xenograft model in nude mice with up to 95% tumor growth inhibition.